(Bloomberg) — Thursday marked another wild day for biotechnology firms as a highly-anticipated presentation from Biogen Inc. took the spotlight and results from neurology-focused peers triggered huge stock swings amid a flurry of reports.When the dust settled in afternoon trading, the presentation from Biogen, combined with key study data from Sage Therapeutics Inc. and Acadia Pharmaceuticals Inc., resulted in a combined $7.6 billion shift in value for the three companies. The huge moves were yet another reminder of how biotechnology investing — and, more specifically, betting on drug development for diseases affecting the brain — can often resemble a roulette …read more
Source:: Yahoo Finance
